Mult Scler. 2007 May;13(4):517-26. Epub 2007 Feb 9.
The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study.Zabad RK, Metz LM, Todoruk TR, Zhang Y, Mitchell JR, Yeung M, Patry DG, Bell RB, Yong VW.
Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Minocycline has immunomodulatory and neuroprotective activities in vitro and in an animal model of multiple sclerosis (MSi). We have previously reported that minocycline decreased gadolinium-enhancing activity over six months in a small trial of patients with active relapsing-remitting MS (RRMSi). Here we report the impact of oral minocycline on clinical and magnetic resonance imaging (MRI) outcomes and serum immune molecules in this cohort over 24 months of open-label minocycline treatment. Despite a moderately high pretreatment annualized relapse rate (1.3/year pre-enrolment; 1.2/year during a three-month baseline period) prior to treatment, no relapses occurred between months 6 and 24. Also, despite very active MRI activity pretreatment (19/40 scans had gadolinium-enhancing activity during a three-month run-in), the only patient with gadolinium-enhancing lesions on MRI at 12 and 24 months was on half-dose minocycline. Levels of the p40 subunit of interleukin (IL)-12, which at high levels might antagonize the proinflammatory IL-12 receptor, were elevated over 18 months of treatment, as were levels of soluble vascular cell adhesion molecule-1. The activity of matrix metalloproteinase-9 was decreased by treatment. Thus, clinical and MRI outcomes are supported by systemic immunological changes and call for further investigation of minocycline in MS. Multiple Sclerosis 2007; 13: 517-526. http://msj.sagepub.com.
PMID: 17463074 [PubMed - in process]
This study draws the conclusion that immunomodulation is the cause of the positive effect of minocycline on MS (see the title!), but since the belief of the researchers is that MS is an immune system disease they were not looking at or for bacteria like CPn.
Well now, that is very
Well now, that is very interesting & done right in my home province Alberta, Canada!!
The neurologist I saw when asked told me there was nooo bacterial connection with MSi & she hasn't been out of "school" that long, she is young & brain washed, lol.
With Christ in Faith
Ruth
Well this work is on
Well this work is on minocycline and how it impacted people with MSi and since it had a positive effect it was determined that the effect was due to the fact that minocylcline damps down the immunei system in a specific way: the matrix mettaloproteinases, IL-12, adhesion molecules were all impacted by treatment in a way that "would" presumably dampen down autoimmunityi. This study if seen by a neurologist would support the autoimmune theory in their minds sadly. but it does give one added reason to partake...
marie
On CAPi since Sept '05 for MS, RAi, Asthmai, sciatica. EDSSi at start 5.5. Currently on: Doxyi 200, Azith 3x week, Tinii cont. since April '07, all supplementsi. "Color out side the lines!"
That both minocyclinei and